Loupe Loupe Logo Sans titre - 2 Logo color EN I-motion_VA_Q Logo White EN I-motion_VA_BL Logo Logo Logo Logo Logo Logo Logo

Opening of the phase III study evaluating mexiletine in children and adolescents with myotonic disorders

MEX-NM-301 clinical study opens at I-Motion. This open-label, non-comparative phase III study aims to evaluate the steady-state pharmacokinetics, safety, and efficacy of Mexiletine in adolescents and children with Myotonic disorders.

Mexiletine is a sodium channel blocker indicated, in adult, in France, for the symptomatic treatment of myotonic syndromes (myotonic dystrophies and non-dystrophic myotonias or channelopathies).

> Further details on MEX-NM-301

Logo white en